Dec 10 (Reuters) - Astria Therapeutics ATXS.O:
ASTRIA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR STAR-0310, A MONOCLONAL ANTIBODY OX40 ANTAGONIST FOR THE TREATMENT OF ATOPIC DERMATITIS
ASTRIA THERAPEUTICS INC: PHASE 1A TRIAL OF STAR-0310 IN HEALTHY VOLUNTEERS EXPECTED TO INITIATE IN Q1 2025
ASTRIA THERAPEUTICS INC: EARLY PROOF-OF-CONCEPT RESULTS EXPECTED IN Q3 2025
Source text: ID:nBw3gg0WFa
Further company coverage: ATXS.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。